Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Madrigal Pharmaceuticals stock

MDGL
US5588681057
A2APCZ

Price

318.89
Today +/-
+14.53
Today %
+4.95 %
P

Madrigal Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Madrigal Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Madrigal Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Madrigal Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Madrigal Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Madrigal Pharmaceuticals Stock Price History

DateMadrigal Pharmaceuticals Price
11/19/2024318.89 undefined
11/18/2024303.49 undefined
11/15/2024288.58 undefined
11/14/2024302.67 undefined
11/13/2024322.88 undefined
11/12/2024339.04 undefined
11/11/2024339.66 undefined
11/8/2024350.70 undefined
11/7/2024354.85 undefined
11/6/2024338.22 undefined
11/5/2024337.61 undefined
11/4/2024331.32 undefined
11/1/2024319.58 undefined
10/31/2024259.34 undefined
10/30/2024215.93 undefined
10/29/2024217.79 undefined
10/28/2024217.00 undefined
10/25/2024210.67 undefined
10/24/2024202.99 undefined
10/23/2024202.48 undefined
10/22/2024203.59 undefined
10/21/2024208.89 undefined

Madrigal Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Madrigal Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Madrigal Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Madrigal Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Madrigal Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Madrigal Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Madrigal Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Madrigal Pharmaceuticals’s growth potential.

Madrigal Pharmaceuticals Revenue, EBIT and net profit per share

DateMadrigal Pharmaceuticals RevenueMadrigal Pharmaceuticals EBITMadrigal Pharmaceuticals Net Income
2029e3.71 B undefined0 undefined2.3 B undefined
2028e2.64 B undefined1.66 B undefined1.44 B undefined
2027e1.93 B undefined1.04 B undefined843.19 M undefined
2026e994.62 M undefined50.93 M undefined46.76 M undefined
2025e506.9 M undefined-444.31 M undefined-310.47 M undefined
2024e172.73 M undefined-627.45 M undefined-525.79 M undefined
20230 undefined-380.5 M undefined-373.63 M undefined
20220 undefined-293.6 M undefined-295.4 M undefined
20210 undefined-242.5 M undefined-241.8 M undefined
20200 undefined-206.7 M undefined-202.2 M undefined
20190 undefined-95 M undefined-83.9 M undefined
20180 undefined-40.7 M undefined-32.8 M undefined
20170 undefined-32.1 M undefined-31.2 M undefined
20160 undefined-25.2 M undefined-26.4 M undefined
20150 undefined-3.2 M undefined-6.8 M undefined
20140 undefined-84 M undefined-86.2 M undefined
20130 undefined-87.6 M undefined-90.2 M undefined
2012100,000 undefined-60.9 M undefined-62.8 M undefined
20117.6 M undefined-45.4 M undefined-47.4 M undefined
201014.8 M undefined-36.9 M undefined-37.5 M undefined
2009144.2 M undefined80.5 M undefined79.1 M undefined
20082.6 M undefined-93.7 M undefined-92.6 M undefined
2007700,000 undefined-66.2 M undefined-122.1 M undefined
20060 undefined-59.2 M undefined-59.1 M undefined
20050 undefined-71.2 M undefined-68.9 M undefined
2004200,000 undefined-45.3 M undefined-45.9 M undefined

Madrigal Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00000000.140.010.010000000000000.170.510.991.932.643.71
-------7,100.00-90.28-50.00-------------194.1996.4494.3736.5440.56
----------------------------
0000000000000000000000000000
-0.04-0.03-0.05-0.07-0.06-0.12-0.090.08-0.04-0.05-0.06-0.09-0.09-0.01-0.03-0.03-0.03-0.08-0.2-0.24-0.3-0.37-0.53-0.310.050.841.442.3
--25.0066.6751.11-13.24106.78-24.59-185.87-146.8427.0331.9145.16-4.44-93.02333.3319.233.23159.38143.3719.3122.4126.4440.75-40.95-114.841,732.6170.7059.83
110.50.60.60.9111.21.31.722.865.212.214.815.415.416.517.118.69000000
----------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Madrigal Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Madrigal Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                         
76.212562.146.8115.673.644.25139.7100.691.597.70.340.5191.5483.7439284.1270.3358.8634.13
000001600.10000000000000
000000000000000000000
000000000000000000000
0.81.10.90.81.41.70.40.40.60.80.81.70.10.70.51.51.211.32.63.15
77126.16347.611791.344.651.540.3101.492.399.40.441.2192485.2440.2285.1271.6361.4637.28
3.24.88.16.15.65.942.21.41.21.61000.30.21.91.81.61.23.27
000000000000000000000
000000000000000000000
000000000000000000000
000000000000000000000
0.11.20.11.10.10.10.40.40.60.51.40.3000000000
3.368.27.25.764.42.621.731.3000.30.21.91.81.61.23.27
80.3132.171.254.8122.797.34954.142.3103.195.3100.70.441.2192.3485.4442.1286.9273.2362.6640.55
                                         
00041.800000000000000000
0.140.240.240.230.320.330.340.370.410.540.60.700.110.290.620.640.670.861.161.74
-64.5-110.4-179.3-236.6-300.1-392.7-313.6-351.1-398.4-461.2-551.4-637.6-48.9-75.3-106.5-139.3-223.2-425.5-667.3-962.7-1,336.29
-2,800-10,600-7,300000000000000-3002000-1000468
000000000000000000000
76.9117.952.44024.8-58.824.923.414.875.149.165.1-48.936.4182.3477416.6239.9196.1197.4405.33
0.22.93.42.62.53.341.93.55.76.63.10.10.81.92.51.2121.423.828.04
2.998.76.19.215.26.66.77.49.916.118.50.148.162445.555.592.190.51
0.30.50.50.56.712.64.64.600000.500000000
00000000000048.600000000
00.51.92.32.42.21.33.54.27.99.59.3000000000
3.412.914.511.520.833.316.516.715.123.532.230.949.34.8108.525.246.576.9115.9118.55
01.24.33.22.820.811.712.44.513.94.7000000049.3115.48
000000000000000000000
000074.2120.76.72.2000000000.40.50.401.19
01.24.33.277122.77.513.912.44.513.94.700000.40.50.449.3116.67
3.414.118.814.797.81562430.627.52846.135.649.34.8108.525.64777.3165.2235.21
80.313271.254.7122.697.248.95442.3103.195.2100.70.441.2192.3485.5442.2286.9273.4362.6640.55
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Madrigal Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Madrigal Pharmaceuticals's financial health and stability.

Assets

Madrigal Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Madrigal Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Madrigal Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Madrigal Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-36-27-45-68-57-63-9279-37-47-62-90-86-6-26-31-32-83-202-241-295-373
0112332211000000000000
0000000000000000000000
0070-48144-112-6-44600-15-619233037-3
2823445159866121431862645415364101
0000000001121000000000
0000000000000000000000
-6-23-33-61-5227-37-26-38-47-54-77-78-3-17-22-25-41-157-183-224-324
00-1-4-1-2-200000000000000-1
-5-40-43392310-2321-199-9-24-8021-22-38030159-5206-502
-5-39-42442513-2121-1910-9-23-8022-21-38030160-4206-501
0000000000000000000000
000-1-2-2-2-2131-410-900000005065
3871830394400313511958940517331405171264530
38718433943-1-24536115698531417331405171313595
0014110000000380000000
0000000000000000000000
2776-18981-63-7-12-151-33-2018129-91-107-17295-231
-6.51-24.38-35.39-66.76-54.5724.87-40.12-27.26-38.34-47.99-54.65-78.18-79.07-3.14-17.61-22.45-25.53-41.79-157.89-184.13-225.08-325.71
0000000000000000000000

Madrigal Pharmaceuticals stock margins

The Madrigal Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Madrigal Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Madrigal Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Madrigal Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Madrigal Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Madrigal Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Madrigal Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Madrigal Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Madrigal Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Madrigal Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Madrigal Pharmaceuticals Margin History

Madrigal Pharmaceuticals Gross marginMadrigal Pharmaceuticals Profit marginMadrigal Pharmaceuticals EBIT marginMadrigal Pharmaceuticals Profit margin
2029e0 %0 %62.05 %
2028e0 %62.89 %54.58 %
2027e0 %53.8 %43.62 %
2026e0 %5.12 %4.7 %
2025e0 %-87.65 %-61.25 %
2024e0 %-363.26 %-304.4 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %-60,900 %-62,800 %
20110 %-597.37 %-623.68 %
20100 %-249.32 %-253.38 %
20090 %55.83 %54.85 %
20080 %-3,603.85 %-3,561.54 %
20070 %-9,457.14 %-17,442.86 %
20060 %0 %0 %
20050 %0 %0 %
20040 %-22,650 %-22,950 %

Madrigal Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Madrigal Pharmaceuticals earnings per share therefore indicates how much revenue Madrigal Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Madrigal Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Madrigal Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Madrigal Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Madrigal Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Madrigal Pharmaceuticals Revenue, EBIT and net profit per share

DateMadrigal Pharmaceuticals Sales per ShareMadrigal Pharmaceuticals EBIT per shareMadrigal Pharmaceuticals Earnings per Share
2029e170.01 undefined0 undefined105.49 undefined
2028e120.95 undefined0 undefined66.02 undefined
2027e88.63 undefined0 undefined38.66 undefined
2026e45.6 undefined0 undefined2.14 undefined
2025e23.24 undefined0 undefined-14.24 undefined
2024e7.92 undefined0 undefined-24.11 undefined
20230 undefined-20.36 undefined-19.99 undefined
20220 undefined-17.17 undefined-17.27 undefined
20210 undefined-14.7 undefined-14.65 undefined
20200 undefined-13.42 undefined-13.13 undefined
20190 undefined-6.17 undefined-5.45 undefined
20180 undefined-2.75 undefined-2.22 undefined
20170 undefined-2.63 undefined-2.56 undefined
20160 undefined-4.85 undefined-5.08 undefined
20150 undefined-0.53 undefined-1.13 undefined
20140 undefined-30 undefined-30.79 undefined
20130 undefined-43.8 undefined-45.1 undefined
20120.06 undefined-35.82 undefined-36.94 undefined
20115.85 undefined-34.92 undefined-36.46 undefined
201012.33 undefined-30.75 undefined-31.25 undefined
2009144.2 undefined80.5 undefined79.1 undefined
20082.6 undefined-93.7 undefined-92.6 undefined
20070.78 undefined-73.56 undefined-135.67 undefined
20060 undefined-98.67 undefined-98.5 undefined
20050 undefined-118.67 undefined-114.83 undefined
20040.4 undefined-90.6 undefined-91.8 undefined

Madrigal Pharmaceuticals business model

Madrigal Pharmaceuticals Inc is a biopharmaceutical company specializing in the development of top-quality therapy products for various metabolic disorders. The company is headquartered in Conshohocken, Pennsylvania and was founded in 2011. The history of Madrigal Pharmaceuticals Inc began with the collaboration of Fred Middleton and Paul Friedman. Both are experienced drug developers and have already achieved some successes in the industry. They discovered the promising active ingredient resveratrol for the treatment of obesity and other metabolic disorders in mice. The idea of applying this concept to humans led to the founding of Madrigal Pharmaceuticals Inc. The business model of Madrigal Pharmaceuticals Inc consists of developing high-quality peptide and lipid-based drugs. The company specifically focuses on the treatment of metabolic disorders such as non-alcoholic fatty liver disease (NAFLD), lipid metabolism disorders, and NASH (non-alcoholic steatohepatitis). The goal is to develop innovative therapy products that bring about significant improvements in patients. Madrigal Pharmaceuticals Inc has several divisions in research and development. One of the most important specialties is the discovery of ACTOS resistance. ACTOS is a drug used to treat diabetic metabolic disorders. However, Madrigal Pharmaceuticals Inc has recognized that ACTOS does not work in some patients, and that this patient group is at higher risk of obesity, NAFLD, and NASH. Therefore, the company is developing therapeutics that target this patient group and are more effective than ACTOS. Another specialty of Madrigal Pharmaceuticals is the Myocardial Peptide Modulator (MMP). This active ingredient is a potential approach to treating metabolic disorders and heart failure. Another important division of Madrigal Pharmaceuticals Inc is the development of drugs targeting PCSK9 inhibition. PCSK9 is a protein that contributes to increased cholesterol levels. The goal is to improve understanding of the mechanism of action of PCSK9 and its various mechanisms in order to develop effective therapy products. The company has already developed several products that are in the clinical phase and are highly effective. One of the most remarkable products is MGL-3196. This product is a farnesoid X receptor agonist that has proven to be promising in the treatment of NASH and lipid metabolism disorders. Madrigal Pharmaceuticals Inc has also formed partnerships with other companies to strengthen collaboration in the research and development of products. One important partnership is with Shionogi, a Japanese pharmaceutical company. This collaboration has helped develop an innovative therapy product for the treatment of obesity that uses a targeted gene silencer. Overall, Madrigal Pharmaceuticals Inc has established itself as a company that develops innovative products for the treatment of metabolic disorders. The company strives to create the possibility for patients to receive effective therapy that is able to improve the mechanism of action of metabolic disorders. Madrigal Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Madrigal Pharmaceuticals SWOT Analysis

Strengths

Madrigal Pharmaceuticals Inc has several key strengths that contribute to its success in the pharmaceutical industry:

  • Strong research and development capabilities, focused on innovative drug development.
  • Unique pipeline of potential blockbuster drugs addressing unmet medical needs.
  • Experienced leadership team with a track record of successful drug development and commercialization.
  • Strong financial position and investment support leading to sustained growth.

Weaknesses

Despite its strengths, Madrigal Pharmaceuticals Inc does face certain weaknesses that may hinder its growth and performance:

  • Reliance on a limited number of drug candidates increases the risk of failure in the development stage.
  • Limited marketing and commercialization capabilities compared to larger pharmaceutical companies.

Opportunities

Madrigal Pharmaceuticals Inc can capitalize on the following opportunities to enhance its position in the market:

  • Growing demand for specialized drugs to treat various metabolic diseases.
  • Expansion into international markets to reach a wider customer base.
  • Potential collaborations and partnerships with larger pharmaceutical companies for research or marketing purposes.

Threats

Madrigal Pharmaceuticals Inc faces certain threats that could pose challenges to its growth and profitability:

  • Intense competition from other pharmaceutical companies, especially in the field of metabolic diseases.
  • Stringent regulatory requirements and potential delays in drug approval processes.
  • Changes in healthcare policies and reimbursement systems that could impact drug pricing and access.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Madrigal Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Madrigal Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Madrigal Pharmaceuticals shares outstanding

The number of shares was Madrigal Pharmaceuticals in 2023 — This indicates how many shares 18.688 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Madrigal Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Madrigal Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Madrigal Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Madrigal Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Madrigal Pharmaceuticals stock splits

In Madrigal Pharmaceuticals's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-7.05 -4.92  (30.22 %)2024 Q3
6/30/2024-7.68 -7.1  (7.5 %)2024 Q2
3/31/2024-6.41 -7.38  (-15.12 %)2024 Q1
12/31/2023-5.39 -5.68  (-5.38 %)2023 Q4
9/30/2023-5.02 -5.34  (-6.3 %)2023 Q3
6/30/2023-4.67 -4.69  (-0.37 %)2023 Q2
3/31/2023-5.04 -4.23  (16 %)2023 Q1
12/31/2022-4.65 -4.98  (-7.16 %)2022 Q4
9/30/2022-4.24 -4.75  (-12.11 %)2022 Q3
6/30/2022-3.77 -4.14  (-9.78 %)2022 Q2
1
2
3
4
5
...
8

Eulerpool ESG Scorecard© for the Madrigal Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

31/ 100

🌱 Environment

32

👫 Social

43

🏛️ Governance

18

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Madrigal Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
11.39730 % Janus Henderson Investors2,485,751-115,5316/30/2024
9.42483 % Avoro Capital Advisors LLC2,055,555111,1116/30/2024
9.05360 % Baker Bros. Advisors LP1,974,5904,7926/30/2024
8.78433 % RTW Investments L.P.1,915,8621,518,8156/30/2024
8.48235 % Paulson & Co. Inc.1,850,00075,0006/30/2024
8.27190 % The Vanguard Group, Inc.1,804,102137,8986/30/2024
5.80662 % BlackRock Institutional Trust Company, N.A.1,266,424183,1956/30/2024
4.99680 % Taub (Rebecca A)1,089,802650,8044/22/2024
4.20389 % Friedman (Paul A)916,8687146/25/2024
3.85727 % T. Rowe Price Associates, Inc.841,27153,0806/30/2024
1
2
3
4
5
...
10

Madrigal Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Roche Holding Stock
Roche Holding
SupplierCustomer0,390,53-0,56-0,52-0,58-0,87
Aldeyra Therapeutics Stock
Aldeyra Therapeutics
SupplierCustomer0,190,670,890,340,480,53
1

Most common questions regarding Madrigal Pharmaceuticals

What values and corporate philosophy does Madrigal Pharmaceuticals represent?

Madrigal Pharmaceuticals Inc is committed to delivering innovative solutions to fight cardiovascular and metabolic diseases. The company's corporate philosophy revolves around prioritizing patient health and improving their quality of life. Madrigal Pharmaceuticals aims to develop and bring to market novel therapies that address unmet medical needs worldwide. By leveraging their expertise in lipid and liver biology, the company focuses on developing drugs that target NASH (nonalcoholic steatohepatitis) and related liver diseases. Through dedicated research, Madrigal Pharmaceuticals strives to create significant value for patients, healthcare providers, and shareholders alike.

In which countries and regions is Madrigal Pharmaceuticals primarily present?

Madrigal Pharmaceuticals Inc is primarily present in the United States.

What significant milestones has the company Madrigal Pharmaceuticals achieved?

Madrigal Pharmaceuticals Inc. has achieved several significant milestones. Firstly, the company successfully completed a Phase 2 clinical trial for its lead drug candidate, MGL-3196, showing promising results in treating non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Additionally, Madrigal Pharmaceuticals obtained Fast Track designation from the U.S. FDA for MGL-3196, highlighting its potential to address unmet medical needs. Furthermore, the company secured a worldwide license agreement with Synta Pharmaceuticals Corp., strengthening its intellectual property portfolio. Madrigal Pharmaceuticals' dedication to developing innovative therapies for metabolic and cardiovascular diseases reflects its commitment to making a profound impact in the pharmaceutical industry.

What is the history and background of the company Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals Inc, founded in 2011, is a clinical-stage biopharmaceutical company specializing in the development of novel, small-molecule drugs for the treatment of cardiovascular and metabolic diseases. Headquartered in West Conshohocken, Pennsylvania, the company has built a strong reputation for its innovative approach to drug discovery. Madrigal's flagship product, MGL-3196, aims to treat non-alcoholic steatohepatitis (NASH), a progressive liver disease. It has shown promising Phase 2 trial results, demonstrating significant reductions in liver fat and key metabolic markers. Madrigal Pharmaceuticals has attracted attention from investors for its focused pipeline and commitment to delivering safe and effective therapies for patients with unmet medical needs.

Who are the main competitors of Madrigal Pharmaceuticals in the market?

The main competitors of Madrigal Pharmaceuticals Inc in the market are Intercept Pharmaceuticals Inc, Viking Therapeutics Inc, and CymaBay Therapeutics Inc.

In which industries is Madrigal Pharmaceuticals primarily active?

Madrigal Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for cardiovascular, metabolic, and liver diseases. The company's business model revolves around identifying and advancing potential drug candidates through rigorous research and clinical trials. Madrigal aims to address unmet medical needs by leveraging its expertise in lipid and liver biology. The company also seeks to pursue strategic collaborations and partnerships to further enhance its pipeline and bring novel treatments to patients.

What is the P/E ratio of Madrigal Pharmaceuticals 2024?

The Madrigal Pharmaceuticals P/E ratio is -11.33.

What is the P/S ratio of Madrigal Pharmaceuticals 2024?

The Madrigal Pharmaceuticals P/S ratio is 34.5.

What is the Quality Investing of Madrigal Pharmaceuticals?

The Quality Investing for Madrigal Pharmaceuticals is 3/10.

What is the revenue of Madrigal Pharmaceuticals 2024?

The expected Madrigal Pharmaceuticals revenue is 172.73 M USD.

How high is the profit of Madrigal Pharmaceuticals 2024?

The expected Madrigal Pharmaceuticals profit is -525.79 M USD.

What is the business model of Madrigal Pharmaceuticals

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapies for metabolic disorders. The company is headquartered in Conshohocken, Pennsylvania and offers a wide range of therapeutic products. The development of Madrigal Pharmaceuticals is characterized by a unique business model that emphasizes high standards in research and development, clinical trials, and marketing. The company collaborates closely with leading scientists, research institutes, and clinicians to produce products that provide effective solutions for patients with various metabolic disorders. The company's different divisions include the area of Non-Alcoholic Fatty Liver Disease (NAFLD), an increasing metabolic disorder characterized by the accumulation of fats in the liver. Madrigal Pharmaceuticals offers several products in this field, including MGL-3196, a drug that has already been approved by the FDA and is considered promising in combating NAFLD and Non-Alcoholic Steatohepatitis (NASH). Another focus of the company is in the area of atherosclerosis, a disease that leads to the hardening and narrowing of arteries. Here, the company offers its next promising drug candidates, including MGL-3745, which has shown effectiveness in lowering LDL cholesterol levels and reducing inflammation in preclinical studies. Madrigal Pharmaceuticals also relies on an innovative business model to optimize product positioning and marketing. The company has collaborative agreements with other bio-pharmaceutical companies to help spread the products and services of Madrigal Pharmaceuticals. To finance the ongoing development of therapies, Madrigal Pharmaceuticals continuously seeks investments in the form of venture capital, public financing rounds, and other financial instruments. The company has a stable network of investors and partners who support the company in achieving its mission. In summary, the business model of Madrigal Pharmaceuticals Inc is highly innovative and focused on the development of therapies for various metabolic disorders such as NAFLD and atherosclerosis. The company relies on close collaboration with pharmaceutical partners, public investments, and a strong network of researchers and scientists. This allows Madrigal Pharmaceuticals to produce products that provide effective solutions for patients with these serious conditions.

What is the Madrigal Pharmaceuticals dividend?

Madrigal Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Madrigal Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Madrigal Pharmaceuticals or the company does not pay out a dividend.

What is the Madrigal Pharmaceuticals ISIN?

The ISIN of Madrigal Pharmaceuticals is US5588681057.

What is the Madrigal Pharmaceuticals WKN?

The WKN of Madrigal Pharmaceuticals is A2APCZ.

What is the Madrigal Pharmaceuticals ticker?

The ticker of Madrigal Pharmaceuticals is MDGL.

How much dividend does Madrigal Pharmaceuticals pay?

Over the past 12 months, Madrigal Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Madrigal Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Madrigal Pharmaceuticals?

The current dividend yield of Madrigal Pharmaceuticals is .

When does Madrigal Pharmaceuticals pay dividends?

Madrigal Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Madrigal Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Madrigal Pharmaceuticals located?

Madrigal Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Madrigal Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Madrigal Pharmaceuticals from 11/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/20/2024.

When did Madrigal Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/20/2024.

What was the dividend of Madrigal Pharmaceuticals in the year 2023?

In the year 2023, Madrigal Pharmaceuticals distributed 0 USD as dividends.

In which currency does Madrigal Pharmaceuticals pay out the dividend?

The dividends of Madrigal Pharmaceuticals are distributed in USD.

All fundamentals about Madrigal Pharmaceuticals

Our stock analysis for Madrigal Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Madrigal Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.